European Pharmaceutical Review
SEPTEMBER 1, 2023
The global mRNA-based oncology therapy market is expected to reach $2 billion by 2029, according to GlobalData. percent share by 2029, the research has shown. percent of the total mRNA therapy market by 2029. BioNTech is anticipated to lead the market with a predicted $885 million in sales, and a 44.6
Pharmaceutical Technology
APRIL 24, 2023
While Imbruvica maintained a previously strong position on the market, competition has chipped away at the inhibitor’s market share. billion in 2029, while Calquence is expected to make $5.31 billion in 2029, while Calquence is expected to make $5.31 billion in 2029. billion in the same year. billion in the same year.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
APRIL 19, 2024
Conclusions from the meeting of the special European Council (17-18 April 2024) have recognised a need for new European competitiveness deal “anchored in a fully integrated Single Market”. The post Enhancing competitiveness of European life sciences appeared first on European Pharmaceutical Review.
European Pharmaceutical Review
AUGUST 21, 2023
billion sales globally by 2029, this could offset Keytruda’s decline sales expected after its loss of exclusivity in 2028, GlobalData highlighted. This is mainly due to the reported decline in sales of Humira, a consequence of biosimilar competition. With the company’s monoclonal antibody drug candidate PRA023 predicted to reach $2.1
Pharmaceutical Technology
JANUARY 10, 2023
Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).
pharmaphorum
SEPTEMBER 30, 2022
Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition for years, and a new judgment looks set to protect its third biggest-selling drug for another few years. 8,414,921), which covers the co-formulation of sitagliptin and metformin and is due to expire in 2029.
Pharmaceutical Technology
MAY 16, 2023
million by 2029. Although Sanofi may face generic drug competition this year for its multiple sclerosis drug, Aubagio, the company is expected to maintain their sales of Dupixent, accounting for 43.3% Sanofi and Regeneron’s market capitalisation grew by 12.4%
Expert insights. Personalized for you.
90 
Let's personalize your content